Monroe Site ‘Critical’ For Glenmark In US
Commercialization From Monroe Site Is Key To Glenmark’s US Step-Up
Executive Summary
Glenmark expects its first US manufacturing site to go commercial next year, accelerating growth in that market, while it sets right certain compliance blips back home. The Indian firm is also on course to divest certain non-core assets but notes that bringing in a minority partner for its API unit is not a priority.
You may also be interested in...
‘Painful’ Few Years In US For Glenmark But Rebound In Sight
With price erosion seen ‘hitting the bottom’ in the US, Glenmark expects to make a strong comeback after some tough years in that market. Much will depend on product flow, including injectables, from the new Monroe site, with investors also keeping an eye on regulatory traction for rhinitis therapy Ryaltris.
Glenmark Sells Gynecology Unit
Glenmark has struck a deal with private equity firm True North for its gynecology business in India and Nepal.
FDA Warning Letter Blasts Glenmark
Glenmark, which has been the recipient of a string of notices from the US Food and Drug Administration over manufacturing quality issues, is again under fire with the regulator blasting the leading Indian drugmaker for failing to ensure “consistent production” of safe and effective products.